Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 123-126

  Milch, Catherine ^a   Wyant, Tim ^a   Xu, Jing ^a   Parikh, Asit ^b   Kent, Whitney ^a   Fox, Irving ^a   Berger, Joseph ^c  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cerebrospinal fluid; Immune surveillance; Inflammatory bowel disease; Vedolizumab

Indexed keywords

CELL MARKER; VEDOLIZUMAB;

ADULT; ARTICLE; BACKACHE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; FAINTNESS; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

CEREBROSPINAL FLUID; IMMUNE SURVEILLANCE; INFLAMMATORY BOWEL DISEASE; VEDOLIZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; CEREBROSPINAL FLUID; FEMALE; HUMANS; INTEGRINS; MALE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84886788747     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.08.011     Document Type: Article

References (15)

1. Berger J.R., Koralnik I.L. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N. Engl. J. Med. 2005, 353:414-416.
2. Clifford D.B., De Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446.
3. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.-F., Sandborn W.J., Van Assche G., Axler J., Kim H.-J., Danese S., Fox I., Milch C., Sankoh S., Wyant T., Xu J., Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013, 369:699-710. GEMINI 1 Study Group.
4. Fedyk E.R., Wyant T., Yang L., Csizmadia V., Burke K., Yang H., Kadambi V.J. Exclusive antagonism of the alpha4beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm. Bowel Dis. 2012, 18:2107-2119.
5. Haanstra K.G., Hofman S.O., Lopes Estevao E.S. Antagonizing the alpha4beta1 integrin but not alpha4beta7 inhibits leukocytic infiltration of the CNS in rhesus EAE. J. Immunol. 2013, 190:1961-1973.
6. Hickey W.F. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 1999, 11:125-137.
7. Major E.O. History and current concepts in the pathogenesis of PML. Cleve. Clin. J. Med. 2011, 78(Suppl. 2):S3-S7.
8. Parikh A., Wyant T., Clifford D.B., Berger J.R., Feagan B.G., Fox I.H., Milch C. No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to α4β7 integrin (Digestive Disease Week 2010 abstract 1008). Gastroenterology 2010, 138(5 Suppl. 1):S145-S146.
9. Sandborn W.J., Feagan B.G., Rutgeerts P., Hanauer S., Colombel J.-F., Sands B.E., Lukas M., Fedorak R.N., Lee S., Bressler B., Fox I., Rosario M., Sankoh S., Xu J., Stephens K., Milch C., Parikh A. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2013, 369:711-721. GEMINI 2 Study Group.
10. Sathish J.G., Sethu S., Bielsky M.C., de Haan L., French N.S., Govindappa K., Green J., Griffiths C.E., Holgate S., Jones D., Kimber I., Moggs J., Naisbitt D.J., Pirmohamed M., Reichmann G., Sims J., Subramanyam M., Todd M.D., Van Der Laan J.W., Weaver R.J., Park B.K. Challenges and approaches for the development of safer immunomodulatory biologics. Nat. Rev. Drug Discov. 2013, 12:306-324.
11. Soler D., Chapman T., Yang L.L., Wyant T., Egan R., Fedyk E.R. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 2009, 330:864-875.
12. Stuve O., Marra C.M., Bar-Or A., Niino M., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Jerome K.R., Cook L., Grand'Maison F., Hemmer B., Monson N.L., Racke M.K. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 2006, 63:1383-1387.
13. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 2006, 59:743-747.
14. Tan C.S., Koralnik I.J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010, 9:425-437.
15. ® (natalizumab) package insert 2011, Biogen Idec Inc., Cambridge, MA.